Natrecor Safety Labeling Change Likely, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is in discussions with FDA to “ensure that correct conclusions are in label.” Adverse publicity from Circulation article questioning kidney safety of CHF drug is having an impact; mortality analysis in JAMA will raise more questions.
You may also be interested in...
Natrecor Concerns Are Limiting Use Of Other IV Vasoactive Therapies As Well, JAMA Finds
Decline in use of other congestive heart failure therapies raises concerns about the effect of articles that question the safety of approved medications.
Natrecor Concerns Are Limiting Use Of Other IV Vasoactive Therapies As Well, JAMA Finds
Decline in use of other congestive heart failure therapies raises concerns about the effect of articles that question the safety of approved medications.
Scios Final Analysis Of Natrecor Trial Finds Two Additional Deaths
Johnson & Johnson subsidiary maintains the additional deaths have “no impact on overall risk/benefit profile” of the heart failure therapy.